Craft

Sera Prognostics

Stock Price

$7.1

2024-10-29

Market Capitalization

$236.2 M

2024-10-29

Revenue

$81 K

FY, 2025

Sera Prognostics Summary

Company Summary

Overview
Sera Prognostics is a health diagnostic company that discovers, develops, and commercializes biomarker tests for the early prediction of preterm birth risk and other complications of pregnancy. It develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies.
Type
Public
Status
Active
Founded
2008
HQ
Salt Lake City, UT, US | view all locations
Website
http://www.seraprognostics.com/
Cybersecurity rating
Sectors

Key People

  • Nadia F. Altomare

    Nadia F. Altomare, Chief Commercial Officer

  • Jay Boniface

    Jay Boniface, Chief Scientific Officer

  • Douglas Fisher

    Douglas Fisher, Chief Business Officer

    • Benjamin G. Jackson

      Benjamin G. Jackson, General Counsel

    LocationsView all

    2 locations detected

    • Salt Lake City, UT HQ

      United States

      2749 E Parleys Way #200

    • Brentwood, NY

      United States

      1155 Long Island Ave, Edgewood

    Sera Prognostics Financials

    Summary Financials

    Revenue (Q1, 2026)
    $14.0K
    Gross profit (Q1, 2026)
    ($28.0K)
    Net income (Q1, 2026)
    ($8.4M)
    Cash (Q1, 2026)
    $4.2M
    EBIT (Q1, 2026)
    ($9.4M)
    Enterprise value
    $234.6M

    Footer menu